Immune checkpoint inhibitor combo efficacious for patients with neuroendocrine carcinoma
A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among patients with rare, high-grade neuroendocrine carcinoma, according ...
Mar 31, 2019
0
3